Market overview
The global oral drug delivery market is worth USD 22.6 bn in 2026 and is forecast to reach USD 46.5 bn by 2036, growing at a 7.5% CAGR. United States is the largest country market and Extended and modified release is the largest by technology segment.
| Scope | Oral drug delivery technologies and enabling dosage forms: extended-release tablets and capsules, orally disintegrating tablets, softgels, enteric and gastro-retentive systems, supplied as technology, excipient systems and contract manufacture. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 21.0 bn |
| Value 2026 | USD 22.6 bn |
| Value 2036 | USD 46.5 bn |
| CAGR 2026-2036 | 7.5% |
| Volume 2026 | 64,179 million units |
| Volume 2036 | 125,840 million units |
| Average price 2026 | USD 0.35 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Oral Drug Delivery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 22.6 bn |
| 2027 | USD 24.3 bn |
| 2028 | USD 26.1 bn |
| 2029 | USD 28.0 bn |
| 2030 | USD 30.1 bn |
| 2031 | USD 32.4 bn |
| 2032 | USD 34.8 bn |
| 2033 | USD 37.5 bn |
| 2034 | USD 40.3 bn |
| 2035 | USD 43.3 bn |
| 2036 | USD 46.5 bn |
Oral Drug Delivery market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Extended and modified release | 34.0% | 31.5% | USD 7.7 bn | 6.7% |
| Softgels and liquid-filled capsules | 24.0% | 23.3% | USD 5.4 bn | 7.2% |
| Orally disintegrating and fast-dissolving | 12.0% | 12.2% | USD 2.7 bn | 7.7% |
| Enteric and targeted release | 14.0% | 14.2% | USD 3.2 bn | 7.7% |
| Solubility-enhanced formulations | 16.0% | 18.7% | USD 3.6 bn | 9.2% |
By therapy
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cardiovascular and metabolic | 26.0% | 24.1% | USD 5.9 bn | 6.7% |
| Central nervous system | 22.0% | 22.4% | USD 5.0 bn | 7.7% |
| Pain and inflammation | 14.0% | 12.4% | USD 3.2 bn | 6.2% |
| Gastrointestinal | 12.0% | 12.2% | USD 2.7 bn | 7.7% |
| Oncology | 14.0% | 17.9% | USD 3.2 bn | 10.2% |
| Other | 12.0% | 11.1% | USD 2.7 bn | 6.7% |
By dosage form
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Tablets | 46.0% | 42.0% | USD 10.4 bn | 6.5% |
| Capsules | 24.0% | 22.0% | USD 5.4 bn | 6.6% |
| Oral liquids | 14.0% | 14.0% | USD 3.2 bn | 7.5% |
| Powders and granules | 8.0% | 8.0% | USD 1.8 bn | 7.5% |
| Films and orodispersible forms | 8.0% | 14.0% | USD 1.8 bn | 13.7% |
By release profile
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Immediate release | 48.0% | 42.0% | USD 10.8 bn | 6.1% |
| Extended release | 34.0% | 36.0% | USD 7.7 bn | 8.1% |
| Delayed or targeted release | 18.0% | 22.0% | USD 4.1 bn | 9.7% |
By drug class
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cardiovascular | 22.0% | 20.0% | USD 5.0 bn | 6.5% |
| Central nervous system | 20.0% | 20.0% | USD 4.5 bn | 7.5% |
| Oncology | 18.0% | 22.0% | USD 4.1 bn | 9.7% |
| Anti-infective | 16.0% | 14.0% | USD 3.6 bn | 6.1% |
| Metabolic and other | 24.0% | 24.0% | USD 5.4 bn | 7.5% |
Top 25 countries for oral drug delivery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 85.0% of 2026 revenue and the 25 countries below together hold 96.1%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 9.0 bn | 40.0% | USD 17.9 bn | 7.1% |
| 2 | China | USD 2.3 bn | 10.0% | USD 5.9 bn | 10.1% |
| 3 | Germany | USD 1.4 bn | 6.0% | USD 2.6 bn | 6.6% |
| 4 | Japan | USD 1.4 bn | 6.0% | USD 2.3 bn | 5.6% |
| 5 | India | USD 1.4 bn | 6.0% | USD 3.5 bn | 10.1% |
| 6 | France | USD 903 mn | 4.0% | USD 1.6 bn | 6.1% |
| 7 | United Kingdom | USD 903 mn | 4.0% | USD 1.7 bn | 6.7% |
| 8 | Italy | USD 677 mn | 3.0% | USD 1.2 bn | 6.0% |
| 9 | Canada | USD 677 mn | 3.0% | USD 1.3 bn | 7.1% |
| 10 | Switzerland | USD 677 mn | 3.0% | USD 1.4 bn | 7.5% |
| 11 | Spain | USD 479 mn | 2.1% | USD 996 mn | 7.6% |
| 12 | Australia | USD 377 mn | 1.7% | USD 786 mn | 7.6% |
| 13 | South Korea | USD 298 mn | 1.3% | USD 619 mn | 7.6% |
| 14 | Netherlands | USD 264 mn | 1.2% | USD 549 mn | 7.6% |
| 15 | Mexico | USD 223 mn | 1.0% | USD 465 mn | 7.6% |
| 16 | Russia | USD 185 mn | 0.8% | USD 382 mn | 7.5% |
| 17 | Turkey | USD 151 mn | 0.7% | USD 312 mn | 7.5% |
| 18 | Poland | USD 115 mn | 0.5% | USD 237 mn | 7.5% |
| 19 | Belgium | USD 97 mn | 0.4% | USD 205 mn | 7.8% |
| 20 | Sweden | USD 84 mn | 0.4% | USD 172 mn | 7.5% |
| 21 | Taiwan | USD 68 mn | 0.3% | USD 140 mn | 7.5% |
| 22 | Indonesia | USD 56 mn | 0.2% | USD 116 mn | 7.5% |
| 23 | Saudi Arabia | USD 45 mn | 0.2% | USD 93 mn | 7.5% |
| 24 | Argentina | USD 34 mn | 0.1% | USD 74 mn | 8.2% |
| 25 | Israel | USD 27 mn | 0.1% | USD 56 mn | 7.5% |
| Rest of world | USD 883 mn | 3.9% | USD 1.8 bn | 7.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Lonza
- Catalent
- Thermo Fisher Scientific
- Evonik
- Colorcon
- Ashland
Group 2: Regional and specialist players
- Aenova
- Ethypharm
- Lubrizol Life Science
- Recipharm
- Siegfried
- CordenPharma
- Pfizer CentreOne
Group 3: Emerging and niche players
- IntelGenx
- Adare Pharma Solutions
- Aprecia Pharmaceuticals
- Elite Pharmaceuticals
- Seppic
- Avadel Pharmaceuticals
- Societal CDMO
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the oral drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.5% is calculated from the resulting values.
The market is divided by technology, by therapy, by dosage form, by release profile, by drug class. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the oral drug delivery market?
The global oral drug delivery market is estimated at USD 21.0 bn in 2025 and USD 22.6 bn in 2026.
How fast will the oral drug delivery market grow?
It is forecast to reach USD 46.5 bn by 2036, a compound annual growth rate of 7.5% from 2026, an increase of USD 24.0 bn.
Which country is the largest market for oral drug delivery?
United States is the largest market by revenue at USD 9.0 bn in 2026, 40.0% of the global total. The three largest countries together hold 56.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 10.1% a year from 2026 to 2036.
Which oral drug delivery segment is largest?
In the by technology split, Extended and modified release is the largest segment with 34.0% of 2026 revenue.
Who are the leading oral drug delivery companies?
Global leaders include Lonza, Catalent, Thermo Fisher Scientific, Evonik.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Biopharmaceutical LogisticsUSD 21.7 bn · 9.0% CAGR
- Pharmaceutical Cold ChainUSD 21.6 bn · 8.0% CAGR
- Cell CultureUSD 23.9 bn · 8.0% CAGR
- SyringeUSD 21.2 bn · 6.5% CAGR
- NanomedicineUSD 20.1 bn · 9.0% CAGR
- Medical BillingUSD 20.0 bn · 11.0% CAGR
- Remote Patient MonitoringUSD 25.7 bn · 16.0% CAGR
- Injectable Drug DeliveryUSD 19.6 bn · 9.0% CAGR
← Ophthalmic Stereoscopic 3D Display Organ Preservation & Perfusion Products →